Kuribayashi, Tadahiro
Ohashi, Kadoaki
Nishii, Kazuya
Ninomiya, Kiichiro
Tsubata, Yukari
Ishikawa, Nobuhisa
Kodani, Masahiro
Kanaji, Nobuhiro
Yamasaki, Masahiro
Fujitaka, Kazunori
Kuyama, Shoichi
Takigawa, Nagio
Fujimoto, Nobukazu
Kubota, Tetsuya
Inoue, Masaaki
Fujiwara, Keiichi
Harita, Shingo
Takata, Ichiro
Takada, Kenji
Okawa, Sachi
Kiura, Katsuyuki
Hotta, Katsuyuki
Funding for this research was provided by:
Okayama University
Article History
Received: 22 November 2023
Accepted: 9 January 2024
First Online: 12 February 2024
Declarations
:
: Dr. Ohashi has received honoraria from Eli Lilly Japan K.K., Novartis Pharma K.K., Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., Kyowa Kirin Co., Ltd., and Novartis Pharma K.K; grants from Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Daiichi Sankyo Co. Ltd., Amgen K.K., and Novartis Pharma K.K; and receipt of research reagents from Genentech, Inc. and Novartis Pharma K.K. outside the submitted work. Dr. Ninomiya has received honoraria from AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., Kyowa Kirin Co., Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., MSD K.K., Ono Pharmaceutical CO., LTD., Takeda Pharmaceutical CO., LTD., Pfizer Japan Inc., Bristol Myers Squibb K.K., Elekta K.K., Janssen Pharmaceutical K.K., and Daiichi Sankyo Co. Ltd. outside the submitted work. Dr. Tsubata has received honoraria from Daiichi Sankyo Co. Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co., Ltd, TAIHO PHARMACEUTICAL CO., LTD., and Bristol Myers Squibb K.K.; and subsidies or donations from Pfizer Health Research Foundation outside the submitted work. Dr. Ishikawa has received honoraria from AstraZeneca K.K. and Nippon Boehringer-Ingelheim Co., Ltd. outside the submitted work. Dr. Kodani has received AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical CO., LTD., Pfizer Japan Inc., TAIHO PHARMACEUTICAL CO., LTD., and Takeda Pharmaceutical CO., LTD. outside the submitted work. Dr. Kuyama has received honoraria from Chugai Pharmaceutical Co. Ltd., Bristol Myers Squibb K.K., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., Pfizer Japan Inc., Eli Lilly Japan K.K., MSD K.K., TAIHO PHARMACEUTICAL CO., LTD., Sanofi K.K., Kyowa Kirin Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Daiichi Sankyo Co., Ltd., Nippon Kayaku Co., Ltd., and Novartis Pharma K.K. outside the submitted work. Dr. Takigawa has received grants and personal fees from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., TAIHO PHARMACEUTICAL CO., LTD., Nippon Boehringer-Ingelheim Co., Ltd., and; grants from Kyowa Hakko Kirin Co., Ltd., Nippon Kayaku Co. Ltd., and Takeda Pharmaceutical Co. Ltd.; and personal fees from AstraZeneca K.K., Pfizer Japan Inc., Merck Japan, MSD K.K., Ono Pharmaceutical Co. Ltd. and Bristol Myers Squibb K.K. outside the submitted work. Dr. Fujimoto received honoraria from Ono Pharmaceutical Co. Ltd., AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., and Nippon Kayaku Co., Ltd. outside the submitted work. Dr. Fujiwara has received honoraria from MSD K.K., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd., Sanofi K.K., and Eli Lilly Japan K.K. outside the submitted work. Dr. Kiura has received honoraria from AstraZeneca K.K., Nippon Boehringer-Ingelheim Co., Ltd., Merk Biopharma, TAIHO PHARMACEUTICAL CO., LTD., Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical CO., LTD., Eli Lilly Japan K.K., Pfizer Japan Inc. Bristol Myers Squibb K.K., NipponKayaku Co., Ltd., Ono Pharmaceutical Co. Ltd., and MSD K.K.; research fund from Nippon Boehringer-Ingelheim Co., Ltd., Ono Pharmaceutical Co. Ltd., Novartis Pharma K.K., Takeda Pharmaceutical CO., LTD., Teijin pharma Ltd., Kyorin Pharmaceutical Co., Ltd., Shionogi Pharma Co., Ltd., Nippon Kayaku Co., Ltd., TAIHO PHARMACEUTICAL CO., LTD., and Chugai Pharmaceutical; and consulting fees from Nippon Kayaku Co., Ltd., and Nipro Corp. outside the submitted work. Dr. Hotta has received honoraria from Pfizer Japan Inc., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Takeda Pharmaceutical CO., LTD., MSD K.K., Bristol Myers Squibb K.K., Ono Pharmaceutical Co. Ltd., Nippon Boehringer-Ingelheim Co., Ltd., and NipponKayaku Co., Ltd.; and research fund from MSD K.K., AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Bristol Myers Squibb K.K., and Abbvie Inc. outside the submitted work.